Adults with an elevated body mass index experienced a modest weight loss averaging a significant percentage while preserving muscle mass after taking a bitter hop extract, according to a clinical trial published July 17, 2026, in the journal Obesity Pillars. Researchers evaluated the specific extract, known as Amarasate, over a 24-week period to track changes in body composition rather than total weight alone.
Clinical Trial Design and Dosage
The study enrolled 150 adults with a baseline body mass index ranging between 25 and 35, categorizing participants from overweight to grade I obesity. According to the published data, the intervention group received a daily dose of 500 mg of Amarasate bitter hop extract, while the control group received a placebo for the duration of the 24-week trial. Investigators structured the trial to assess how the bitter compound influences fat distribution and metabolic risk factors alongside overall weight.
Fat Reduction Versus Muscle Retention
Participants in the bitter hop extract group achieved an average weight loss of a significant percentage, or about 3.8 kg, compared to a fractional percentage, or 0.4 kg, in the placebo group. Fat mass decreased by 4.5 kg in the treatment group versus 0.7 kg for controls. Visceral fat, a key marker for metabolic disease, dropped by 33 cm² in the intervention arm compared to 9 cm² in the placebo group. Unlike standard weight loss programs that frequently deplete lean tissue, the intervention group saw an average muscle mass increase of 1 kg, whereas the placebo group recorded a 0.3 kg increase.
Physiological Mechanisms and Future Research
Bitter receptors located within the digestive tract play a central role in transmitting signals related to satiety and metabolic regulation, offering a physiological basis for the observed results. The research team noted that bitter compounds may influence appetite while directing weight reduction toward fat stores rather than muscle tissue. Authors of the study emphasize that these findings apply specifically to adults with a BMI between 25 and 35 utilizing the 500 mg daily formulation of Amarasate, indicating that further long-term studies are necessary to evaluate whether these body composition changes persist across broader populations.
Keep reading